Posted on Monday, February 4th, 2013 | In Biotech
Contributed by: M. E. Garza (http://www.biomedreports.com) -
Arca Biopharma (NASDAQ: ABIO) was a very boring ticker in 2013 until the company provided an update on a proposed clinical trial for atrial fibrillation for the company’s flagship drug Gencaro (bucindolol hydrochloride) after the closing bell on January 29th.
About M. E. Garza (http://www.biomedreports.com)
M.E. Garza is the Co-Founder of BiomedReports.com. A two-time Emmy nominated television producer and entrepreneur, Garza's background in media, writing, marketing and public affairs has allowed him to lead and establish various companies in the broadband, entertainment and communications field. He resides in Los Angeles and his passion is tracking the latest advances in biotechnology- which gives him "great hope and promise" for the future of mankind. He is a constant student of the market who believes that the biotech sector is completely unique and dynamic sector- where everything from research to financial models and the rules for market analysis from other sectors just don't apply. He hopes to help guide BioMedReports into a leading publication that will help investors realize the potential of this revolution in finance and science, while shining the spotlight on companies that are attempting to change our lives in so many beneficial ways.